1155-80 Morbidity and mortality associated with retroperitoneal bleeding following percutaneous coronary intervention with femoral artery access  by Laham, Charles L
88A ABSTRACTS - Angiography & Interventional Cardiology JACC March 3, 2004
An
gi
og
ra
ph
y 
&
 In
te
rv
en
tio
na
l C
ar
di
ol
og
y
Europe and South America. Baseline demographics and lesion characteristics were
evenly distributed. No acute, subacute or late thrombosis occurred. The two-years results
are shown below 
Conclusion: The QCA data demonstrate virtually no neointimal in-stent proliferation and
very little TLR and TVR within the Sirolimus group, and with event-free survival of 90% at
two years. Three-year clinical follow-up data will be presented.
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1155-77 Clinical, Angiographic, and Intravascular Ultrasound 
Comparisons Between Patients With Early Versus Late 
Saphenous Vein Graft Failure
Daniel Arthur Canos, Gary S. Mintz, Jose R. Cordero, Esteban Escolar, Jun-Ichi Kotani, 
Natalie Gevorkian, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Neil J. 
Weissman, Medstar Research Institute, Washington, DC
Background: Up to 20% of saphenous vein grafts (SVG) fail in the 1st yr. The etiology of
early failure is not well understood. Methods: We used coronary angiography and intra-
vascular ultrasound (IVUS) to analyze 100 pts (121 lesions) with early (<1 yr) SVG failure
and 200 pts (289 lesions) with late (>1yr) SVG failure. IVUS assessment included refer-
ence and lesion SVG, lumen, and plaque areas; plaque burden (SVG/plaque area);
remodeling (lesion/reference SVG area); and morphology.
Results: Risk factors were identical in both groups: smoking (44%), diabetes (36%),
hypercholesterolemia (70%), and hypertension (63% early vs 72% late, p = 0.14). Early
failure pts had more anginal rest pain (34.3% vs.19.8%). Comparing early to late failure,
lesion location was proximal in 62% vs 42% (ostial in 37% vs 18%), mid-segment in 13%
vs 29%, distal in 13% vs 20%, and distal anastomosis in 13% vs 5%. Lesion length was
similar (9.6 vs 9.27 mm, p= 0.7). The early failure group had smaller references (IVUS
and angio: 2.74± 0.86 vs 3.26± 0.83 mm, p< 0.01) and little remodeling at the lesion site.
Conversely, late failure lesions had significantly less reference segment plaque burden,
but more mobile plaque elements (21.4% vs 0%, p= 0.01) and calcific plaque (17.9 % vs.
0%, p= 0.02).
Conclusion: Early SVG failure occurs more often at the ostium. Grafts failing <1yr have
more reference segment plaque and less lesion site remodeling suggesting a more
aggressive disease process with intrinsic graft fibrosis. 
1155-78 Implications and Prevention of Large Periprocedural 
Myocardial Infarction After Percutaneous Intervention 
of Diseased Saphenous Vein Grafts and Thrombotic 
Native Coronary Lesions
Zoran Lasic, Roxana Mehran, Eugenia Nikolsky, Manuela Negoita, Ricardo Costa, David 
A. Cox, Joseph Babb, Dean Nukta, Luc Bilodeau, Louis Cannon, Thomas D. Stuckey, 
James Hermiller, Alexandra Lansky, Martin B. Leon, Gregg W. Stone, Lenox Hill Hospital, 
New York City, NY
Background: Peri-procedural myonecrosis after percutaneous coronary intervention
(PCI) is especially common after intervention in saphenous vein grafts (SVG) and throm-
botic lesions, and is strongly associated with worse short and long-term outcomes, espe-
cially when the CPK-MB is >8x normal or Q-wave MI develops. Whether thrombectomy
can decrease the incidence of large peri-procedural myocardial infarctions and improve
outcomes in these high risk situations is unknown.
Methods: We analyzed the effectiveness of thrombectomy with the ev3 X-SIZER in pre-
venting large peri-procedural MIs (Q-wave or CK-MB >8x nl) in the multicenter prospec-
tive X-TRACT trial, in which 797 pts undergoing PCI of diseased SVGs and thrombus
containing native coronary arteries were randomized to thrombectomy vs. control prior to
stenting.
Results: Baseline clinical and demographic data were similar in both groups. Definite
thrombus was present in 191 (47.8%) X-SIZER patients and 164 (41.3%) of control
patients (p<0.07). A total of 60 patients (7.5%) developed a large MI within 30-days after
PCI, including 22 (2.7%) in X-SIZER group and 38 (4.7%) in control group, p<0.03. Large
MI within 30-days after PCI occurred in 10.1% of pts with definite thrombus vs. 5.4% of
pts without definite thrombus (p<0.01). Among pts with thrombus, X-SIZER use
decreased the occurrence of large MI from 14% to 6.8%, p<0.03. The 30-day rate of
repeat target vessel revascularization was increased in pts with vs. without large MI
(8.3% vs. 1.1%, p=0.001). Six-month mortality occurred in 5.0% of patients with CK-MB
>8x normal, compared to 2.4% of pts without CPK-MB >8x normal (p=0.193).
Conclusion: Large peri-procedural myocardial infarctions after intervention in diseased
SVGs and thrombus containing native coronary arteries is associated with an increased
need for early target revascularization, and a trend for increased late mortality. Throm-
bectomy with the X-SIZER prior to stent implantation in these high risk lesions reduces
the occurrence of large peri-procedural myocardial infarctions. Larger studies are
required to demonstrate whether this directly results in a survival advantage with throm-
bectomy.
1155-79 Drug-Eluting Balloon: A New Technique to Deliver 
Paclitaxel to the Angioplasty Site
Kai Hogrefe, Kamal Chitkara, Anthony H. Gershlick, University of Leicester, Leicester, 
United Kingdom
Background:
Paclitaxel, which stabilizes microtubules and renders the affected cell incapable of prolif-
eration and migration, has been shown to reduce neointimal formation. Paclitaxel-loaded
stents have been successfully used in the clinical setting to deliver this very potent agent
to the vessel wall. There are, however, situations such as in- or persistent restenosis or
small vessel angioplasty when a drug eluting stent might not be ideal because of the
thrombosis risk or when their use is inappropriate (edge residual stenosis). In this exper-
iment we loaded paclitaxel onto conventional angioplasty balloon and delivered it to
human arterial wall ex vivo.
Methods:
Whole angioplasty balloons were inflated and then loaded with paclitaxel by immersing
(for 1 hour) into paclitaxel solution (10 mg/ml and 20 mg/ml) spiked with radiolabelled-
paclitaxel. After air-drying, the balloons were placed in scintillation fluid and beta-
counted. Elution of loaded paclitaxel was measured in buffer and blood for up to 10 min.
Paclitaxel loaded balloons were placed inside fresh internal mammary arteries (IMA)
segment, incubated at 37°C and were inflated at 8 atmospheric pressure for 1 and 10
minutes. Intramural deposition was measured after flushing the vessel segment with 5
mls of blood.
Results:
Paclitaxel was loaded successfully onto conventional angioplasty balloon of various
sizes. Corrected for balloon surface area, we achieved paclitaxel loading of 0.22 µg/mm²
after immersion in 10mg/ml paclitaxel solution and 0.37 µg/mm² in 20 mg/ml (p=0.005).
There was little paclitaxel elution in blood and in buffer in the first 10 min (6.2% and 9.7%
respectively). Further, 34.8% paclitaxel was deposited in the artery wall after 1 minute
and 36.7% after 10 minute balloon inflation.
Conclusion:
Paclitaxel can be successfully loaded onto an angioplasty balloon. There was minimal
loss of paclitaxel into blood and up to 34.8% delivery efficiency into internal mammary
artery after 1 minute balloon inflation. Further studies with this novel drug eluting balloon
(DEB) are ongoing to evaluate its effect on smooth muscle cell proliferation in vitro and
restenosis in vivo. Restenosis after balloon angioplasty alone may be reduced.
1155-80 Morbidity and Mortality Associated With Retroperitoneal 
Bleeding Following Percutaneous Coronary 
Intervention With Femoral Artery Access
Charles L. Laham, Mayo Clinic, Rochester, MN
Background: Little is known of the clinical sequelae of retroperitoneal bleeding (RPB) fol-
lowing a femoral access percutaneous coronary intervention (PCI).
Methods and Results: We analyzed the Mayo PCI database and identified 55 patients
(pts) with RPB between 12/01/93 and 6/30/02. We matched 4 pts (controls) without RPB
(total n=220) for each RPB pt based on gender, age within 5 years and PCI within 1 year.
Adverse events in-hospital and at 6 months were analyzed. Among RPB pts, PCI was
Sirolimus Control P-value
Reference diameter (mm) 2.60 2.64 NS
MLD Post-procedure (mm) 2.43 2.41 NS
MLD Follow-up (mm) – 6 month 2.42 1.64 .0001
Late loss (mm) 0.01 0.80 .0001
Restenosis rate (%) 0.0 26.1 .0001
TLR-free – 2 years 97.4 86.2 .0001
TVR-free – 2 years 96.6 83.6 .0001
TVF-free – 2 years 94.1 78.7 .0001
MACE-free – 2 years 90.0 80.5 .0001
IVUS
Characteristics
Early Failure (<1yr) Late Failure (>1yr) p
Distal SVG Area mm2 14.2 ± 7.9 14.6 ± 7.9 0.84
Lumen Area mm2 6.8 ± 5.2 9.9 ± 4.9 0.03
Plaque Burden % 52 ± 17 34 ± 12 <0.01
Proximal SVG Area mm2 14.0 ± 9.5 18.8 ± 7.2 0.08
Lumen Area mm2 6.8 ± 7.9 11.4 ± 4.5 0.02
Plaque Burden 54 ± 19 38 ± 12 0.02
Lesion SVG Area mm2 13.7 ± 7.3 16.8 ± 4.8 0.07
Lumen Area mm2 2.1 ± 1.2 5.0 ± 3.5 < 0.01
Remodeling 0.97 ± 0.23 1.07 ± 0.21 0.09
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less often successful (95 vs. 78%, p=0.001) and more likely to be associated with a pro-
cedural MI (15 vs. 4%, p=0.005). RPB pts had a 20% in-hospital mortality vs. 3% for con-
trols (p<0.001). Event frequencies at 6 months (with Kaplan-Meier estimated rate) are
depicted below:
Conclusions: RPB is a serious complication associated with severe in-hospital and 6
month morbidity and mortality
1155-81 Radiation Exposure to Patients During Diagnostic 
Cardiac Catheterization
Kunadian Vijayalakshmi, Dee Kelly, David Williams, Mark A. de Belder, The James Cook 
University Hospital, Middlesbrough, United Kingdom
Cardiac catheterisation is a widely performed procedure. Ionising radiation during these
procedures results in an increased risk of radiation induced effects. Cardiac investiga-
tions vary in their complexity according to the information being sought. Exposure time
and radiation risks of such procedures are not fully documented. An estimation of the
effective dose (ED) can be obtained from the measurements of the dose-area product
(DAP). Published reports state an estimate of 2.5% per Sievert lifetime risk of fatal cancer
for a population between the ages of 40 and 60 years.
Aims and methods: A retrospective analysis of adult cardiac procedures was carried
out in a regional cardiothoracic unit to determine the DAP, ED and estimated risk of
malignancy. We compared 7 diagnostic groups (Table 1). Dose-area product meter (Dia-
mentor PTW, Freiberg) attached on the X-ray unit (Philips Polydiagnost C2 image intensi-
fier system) was used for the estimation of the radiation dose received by the patient
during the procedures.
Results: A total of 4,706 different procedures were studied (Table 1). Average age and
weight of the patients were 60.9 years and 79.5 kgs respectively.
Conclusions: Cardiac angiographic procedures other than a straightforward investiga-
tion of native coronaries ± left venticulography are associated with significantly high radi-
ation doses. Patient exposure is particularly high in those undergoing graft studies
(p=0.0001).
1155-82 Reduced Fluoroscopy Time and Cine Sequences With 
Digital Flat Panel Technology
Christopher L. Sarnoski, Peter J. Higgins, Thomas J. Ryan, Jr., Mirle A. Kellet, Jr., 
William A. Dietz, Priya Gopinath, Maine Medical Center, Portland, ME, G.E. Medical 
Systems, Waukesha, WI
Background: Digital Flat Panel Systems (DFPS) (GE Innova 2000TM, Waukesha, WI)
have been shown to provide real time cardiac images with improved image quality at
lower radiation doses in comparison to conventional Image Intensifier Systems (IIS).
There is no data showing that the use of this technology impacts resources and patient
care. We have hypothesized performing percutaneous cardiac intervention(PCI) with
DFPS will lead to shorter case time, fluoroscopy time, number of cine runs, and less con-
trast.
Methods: All PCI’s performed using DFPS and IIS during the year 2002 by four high vol-
ume operators were reviewed. Single vessel, single stent procedures without diagnostic
angiography were selected. Patients were matched for body surface area (BSA), artery,
guide size, stent length and diameter. A total of 133 patients were analyzed(85 IIS cases,
48 DFPS cases).
Results: Table 1.
Conclusion: On average, the operator spent 15% less time (p<0.05) using fluoroscopy
and took 12% fewer cines (p<0.05) using DFPS. While there is a trend towards less con-
trast use and shorter case length times with DFPS, the mean values did not reach statis-
tical significance. Using DFPS leads to less fluoroscopy time and cine runs which may
ultimately decrease the amount of radiation exposure to both staff and patients. A more
complex patient population(larger BSA) or intervention(multivessel) may yield even
greater benefits.
1155-83 A Pooled Analysis of Sirolimus and Paclitaxel-Eluting 
Stent Trials
Mohan Babapulle, Mark J. Eisenberg, Jewish General Hospital, Montreal, PQ, Canada
Background: Several clinical trials have examined the efficacy of drug-eluting stents
(DES) at reducing restenosis rates following percutaneous coronary intervention.
Although DES appear to decrease restenosis rates, a pooled analysis has not been pub-
lished that examines treatment effect.
Methods: We performed a pooled analysis of 4 clinical trials involving over 1,700
patients examining Sirolimus-eluting stents, and 5 trials involving over 1,900 patients
examining Paclitaxel-eluting stents. The outcomes of interest were binary restenosis
rates and major adverse cardiac event rates (MACE) (composite of death, myocardial inf-
arction and target lesion revascularization).
Results: In each trial, the treatment group showed lower binary restenosis rates and
lower MACE rates compared to the control group (Table 1). In-stent or in-segment binary
restenosis rates were reduced by 89% (95% Confidence Interval (CI) 84-92%) in Siroli-
mus-eluting stent trials and by 67% (95% CI 55-76%) in Paclitaxel-eluting stent trials.
MACE rates were reduced by 72% (95% CI 63-79%) in Sirolimus trials and by 40% (95%
CI 21-54%) in Paclitaxel trials. For all trials combined, DES were associated with an 81%
reduction in binary restenosis rates (95% CI 76-85%), and a 59% reduction in MACE
rates (95% CI 51-76%). 
Conclusions: Sirolimus and Paclitaxel-eluting stents substantially reduce restenosis and
MACE rates over the short and mid-term.
Table 1. Pooled Analysis of Sirolimus and Paclitaxel Eluting Stent Trials 
Adverse events Controls 
(n=220)
RPB patients 
(n=55)
Hazard 
Ratio
P-
value
Death 10 (4.6) 16 (29) 7.20 <0.00
1
Death/MI 30 (14) 20 (36) 3.06 <0.00
1
Death/MI/Angina 55 (25) 21 (38) 1.71 0.037
Death/MI/Angina/
Revascularization
64 (23) 23 (42) 1.62 0.047
Table 1
Screening time, DAP, ED and estimated risk of malignancy for diagnostic 
cardiac imaging [Mean ± SD]
Groups Nu
mb
er
Screening 
time 
(seconds)
DAP 
(Gy/
Cm2)
ED 
(mS
v)
Estimated risk of 
malignanacy (%)
Group 1 (Coronary 
angiography)
54
9
248 ± 325 15.7 ± 
13
3.4 0.008%
Group 2 (Coronary angiography 
+ left ventriculography-LHC)
35
28
200 ± 243 16.8 ± 
9
3.7 0.009%
Group 3 (Combined right heart 
catheterisation + LHC)
21
7
524 ± 387 28.8 ± 
15
6.3 0.015%
Group 4 (Left ventriculography 
+ aortography)
11 437 ± 470 26.5 ± 
11
5.8 0.014%
Group 5 (LHC + aortography) 16
8
416 ± 424 26.5 ± 
14
5.7 0.014%
Group 6 (LHC + graft study) 18
9
700 ± 518 31.3 ± 
14
6.8 0.0175
Group 7 (LHC + aortography + 
graft study)
44 721 ± 355 39.9 ± 
18
8.6 0.0215%
Mean Value Image
Intensifier
System
Digital Flat Panel System
(GE Innova 2000)
p Value
Fluoroscopy Time (minutes) 10.6 9.0 0.016
Number of Cine Runs 21.0 18.5 0.002
Total Case Time(minutes) 34.0 32.0 0.465
Volume of Contrast (cc) 250.0 234.0 0.152
Trial Coating Binary Restenosis 6-8 
months
MACE 6-12 months
Treatment Control Treatment Control 
RAVEL Sirolimu
s
0/120 31/118 6/120 35/118
C-
SIRIUS
Sirolimu
s
1/43 23/43 2/50 9/50
SIRIUS Sirolimu
s
31/348 128/353 52/533 130/525
E-
SIRIUS
Sirolimu
s
9/152 67/156 14/175 40/177
Sirolimus-Pooled 
(%)
41/663 (6.2) 249/670 (37.2) 74/878 (8.4) 214/870 (24.6)
Taxus I Paclitaxe
l
0/30 3/29 0/31 3/30
Taxus II Paclitaxe
l
19/255 67/263 27/266 57/270
ASPECT Paclitaxe
l
8/100 15/55 10/117 3/59
DELIVER Paclitaxe
l
38/228 48/214 53/517 68/512
ELUTES Paclitaxe
l
4/138 7/35 15/152 7/38
Paclitaxel-Pooled 
(%)
69/751 (9.2) 140/596 (23.5) 105/1083 
(9.7)
138/909 (15.2)
Total (%) 110/1,414 
(7.8)
389/1,266 
(30.7)
179/1,961 
(9.1)
352/1,779 
(19.8)
